Oragenics (OGEN)
(Delayed Data from AMEX)
$1.27 USD
+0.25 (24.51%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $1.28 +0.01 (0.79%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Oragenics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 15 | 16 | 27 | 16 |
Income After Depreciation & Amortization | -21 | -14 | -16 | -27 | -16 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -21 | -14 | -16 | -26 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -21 | -14 | -16 | -26 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -21 | -14 | -16 | -26 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -21 | -14 | -16 | -27 | -16 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -21 | -14 | -16 | -27 | -16 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.25 | 2.01 | 1.89 | 0.94 | 0.71 |
Diluted EPS Before Non-Recurring Items | -9.18 | -7.11 | -8.38 | -28.14 | -22.16 |
Diluted Net EPS (GAAP) | -9.18 | -7.11 | -8.38 | -28.14 | -22.16 |
Fiscal Year end for Oragenics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
SG&A, R&D, and Dept/Amort Expenses | 2.31 | 2.46 | 12.79 | 2.10 | 3.13 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.31 | -2.46 | -12.79 | -2.09 | -3.12 |
Non-Operating Income | 0.00 | 0.02 | 0.06 | 0.10 | 0.06 |
Interest Expense | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 |
Pretax Income | -2.31 | -2.45 | -12.75 | -2.01 | -3.05 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.31 | -2.45 | -12.75 | -2.01 | -3.05 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.31 | -2.45 | -12.75 | -2.01 | -3.05 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.53 | 3.50 | 2.25 | 2.36 | 2.03 |
Diluted EPS Before Non-Recurring Items | -0.51 | -0.70 | -5.48 | -0.85 | -1.51 |
Diluted Net EPS (GAAP) | -0.51 | -0.70 | -5.41 | -0.85 | -1.51 |